Delivering on the untapped potential of peptides
Ra Pharma™ is developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules. Our peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability. We are leveraging our technology to rapidly generate drug candidates to develop our own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches for addressing unmet medical needs.
Ra Pharmaceuticals Appoints Pamela Esposito, Ph.D., as Chief Business Officer More »
Ra Pharmaceuticals Announces Broad Collaboration with Merck to Develop Cyclomimetics™. More »
Dr. Douglas Treco, CEO and Dr. Jack W. Szostak discuss their upcoming talks at the Inaugural Constrained Peptides and Macrocyclics Drug Discovery Conference. More »